In December 2018, BioNova completed Series A financing with TF Capital and Hillhouse Capital being the lead investors.
In August 2020, BioNova completed Series B financing with OrbiMed and BioTrack Capital being the lead investors.
In November 2020, BioNova completed Series B+ financing, co-invested by Hanne Capital, GP Capital, Med-Fine Capital, Yunion Capital, and Rencent Capital.
From biopharmaceuticals to medical devices, diagnostics, and healthcare services, OrbiMed is scouting the globe for innovations that will help ensure humanity lives healthier, longer and more productive lives.
OrbiMed invests across the global healthcare industry, from seed-stage venture capital to large publicly-traded companies. Investments are made in one of three strategies: public equity, private equity, and private credit/royalty.
Specializes in start-up angel investment for biomedicine and biotechnology professionals. Captures investment opportunities through years of networking and invests in outstanding entrepreneurial teams.
Builds businesses that stand the test of time. Looks for opportunities around the globe, with a focus on Asia, and have the flexibility to work across the equity spectrum, from seed investments to buyouts and listed equities. Deploys technology to drive innovation, with sustainable, long-term growth as the ultimate goal.
Founded in 2008, LAV is dedicated to venture capital investments in the life sciences and healthcare sectors in Asia, particularly in China. As a leading biomedical venture fund in China, LAV provides wise capital, industry expertise, and global resources to its portfolio companies to accelerate their growth.
Med-Fine Capital focuses on investment in the fields of medical health and life sciences, with offices in Shanghai, Beijing and Shenzhen. The management team has broad international vision, profound industrial background, rich industry resources and professional investment experience. The fund focuses on "early value and on-track opportunity discovery", and focuses on investment opportunities in biomedicine, device diagnosis and digital medical care. About 60 pharmaceutical companies have invested, including Pharma Legacy，MagAssist , Alebund, Allorion Therapeutics , CommBio Therapeutics, SAFE Pharmaceutical, Ansong Technology and Willing Med.
Combining "decentralized investment" and "systematic operation", with the vision of "outlining the life sciences skyline", and adhering to the concept of "making good use of capital power and returning trust", Mid-Fine Capital is committed to becoming an open, platform-based company , A professional investment institution with outstanding competitiveness and far-reaching reputation.
Mitsui Global Investment (MGI), a 100% subsidiary of Mitsui & Co. Ltd., was established in 1996, with its headquarters in Silicon Valley and branches in Tokyo and Beijing. MGI has been engaging in investments in startups and focus areas covering IT and communication, healthcare and biotech and industrial opportunities. Since its establishment, MGI has invested in and managed over 100 portfolio companies. Our vision is to leverage Mitsui’s global network and provide portfolio companies support to build their business and guide them onto the global stage.
Focuses on investment in the life sciences industry, primarily investing in early stage companies with high potential. Through strategic investments in various key areas and right partnerships, TF Capital hopes to capture opportunities in the rapidly expanding Chinese life sciences market.
Founded in 2017, Hanne Capital is a healthcare venture capital fund focusing on growth opportunities in the Greater China. The Founding Partners are industry veterans with years of senior leadership experience in leading private equity fund or world-renowned multinationals in biotech, pharma and medtech; and have accomplished significant industry milestones in their previous careers. The Hanne team consists of seasoned professionals with sharp business acumen, rich experience of investment and entrepreneurial background.
Yunion Healthcare Ventures (YUNION) is a research based VC fund founded in early 2019. With top Chinese Big Pharma as cornerstone investors, YUNION invests globally in biotech companies with cutting edge technologies in the sectors of pharmaceutics, diagnostics, and medical devices. YUNION also incubates early stage biotech startups with top industrial experts, R&D scientists, professors, and translational veterans, to provide innovative technologies and pipelines.
GP Healthcare Capital is a professional fund focusing on equity investment in the medical and health industry, with a management scale of over ￥ 2 billion. Since 2015, it has invested in more than 40 companies in the fields of biotechnology and pharmaceuticals, medical devices, IVD, and medical services, all of which are in a leading position in the industry. GP Healthcare Capital has a corporate culture of sharing and growth, and is committed to becoming a value discoverer and value creator, and accompanies outstanding entrepreneurs to grow together.
Rencent Capital is a global investment institution with a management scale of nearly 10 billion RMB. It currently has investment management offices in Beijing, Hong Kong, Qingdao and Shanghai.
Rencent Capital pursues long-term structural value investment and looks for industry pioneers with long-term competitiveness. Through the thorough understanding of China's macro and micro economic trends and comprehensive analysis of the global market situation, Rencent Capital focuses on leading enterprises with unique competitive advantage in fields such as medical health, scientific and technological innovation and big consumption, provides financial support at all stages from start-up to post-IPO. The investment category includes fund investment and direct equity investment.